Home Page
WuXi Biologics has authorized Exelixis exclusively to expand its oncology biological drug production. WuXi AppTec, which includes WuXi Biologics, has 14 plants, with half in the U.S. and half in China. WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×Contact Us
For More Info!
